These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 12537941)

  • 1. Antisense oligonucleotide therapy for urologic tumors.
    Kausch I; Böhle A
    Curr Urol Rep; 2003 Feb; 4(1):60-9. PubMed ID: 12537941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense therapy in clinical oncology: preclinical and clinical experiences.
    Tamm I
    Methods Mol Med; 2005; 106():113-34. PubMed ID: 15375315
    [No Abstract]   [Full Text] [Related]  

  • 3. [Basics of antisense oligonucleotide therapy and current therapeutical strategies in urology].
    Kausch I; Böhle A
    Aktuelle Urol; 2003 Dec; 34(7):458-68. PubMed ID: 14655082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical studies of antisense oligonucleotides for cancer therapy.
    Orr RM; Dorr FA
    Methods Mol Med; 2005; 106():85-111. PubMed ID: 15375314
    [No Abstract]   [Full Text] [Related]  

  • 5. Antisense oligonucleotide therapy in urology.
    Kausch I; Böhle A
    J Urol; 2002 Jul; 168(1):239-47. PubMed ID: 12050550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of BCL2 by Antisense Oligonucleotides and Compensation by Non-Targeted Genes May Enhance Tumor Proliferation.
    Rubenstein M; Hollowell CM; Guinan P
    In Vivo; 2015; 29(6):687-93. PubMed ID: 26546525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
    Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
    Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor regression by combination antisense therapy against Plk1 and Bcl-2.
    Elez R; Piiper A; Kronenberger B; Kock M; Brendel M; Hermann E; Pliquett U; Neumann E; Zeuzem S
    Oncogene; 2003 Jan; 22(1):69-80. PubMed ID: 12527909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxicity of etoposide in cancer cell lines in vitro after BCL-2 and C-RAF gene silencing with antisense oligonucleotides.
    Sypniewski D; Bednarek I; Gałka S; Loch T; Błaszczyk D; Sołtysik D
    Acta Pol Pharm; 2013; 70(1):87-97. PubMed ID: 23610963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
    Holmlund JT; Monia BP; Kwoh TJ; Dorr FA
    Curr Opin Mol Ther; 1999 Jun; 1(3):372-85. PubMed ID: 11713802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of Ras, Raf and L-myc but not Bcl-2 family proteins is linked with resistance to TCR-mediated apoptosis and tumorigenesis in thymic lymphomas from TCR transgenic mice.
    Kobzdej M; Matuszyk J; Strzadala L
    Leuk Res; 2000 Jan; 24(1):33-8. PubMed ID: 10634643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins.
    Gautschi O; Tschopp S; Olie RA; Leech SH; Simões-Wüst AP; Ziegler A; Baumann B; Odermatt B; Hall J; Stahel RA; Zangemeister-Wittke U
    J Natl Cancer Inst; 2001 Mar; 93(6):463-71. PubMed ID: 11259472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oligonucleotide treatment of ras-induced tumors in nude mice.
    Wickstrom E
    Mol Biotechnol; 2001 May; 18(1):35-55. PubMed ID: 11439698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product.
    Smythe WR; Mohuiddin I; Ozveran M; Cao XX
    J Thorac Cardiovasc Surg; 2002 Jun; 123(6):1191-8. PubMed ID: 12063468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Up-expression of IL-6 and down-expression of TNFalpha may be involved in the regulation of apoptosis induced by antisense bcl-2 oligodeoxynucleotides].
    Chen X; Hu J; Chen Z; Lu L
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Dec; 19(6):495-8. PubMed ID: 12476423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
    Zupi G; Scarsella M; Semple SC; Mottolese M; Natali PG; Leonetti C
    Clin Cancer Res; 2005 Mar; 11(5):1990-8. PubMed ID: 15756025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. c-myc antisense oligodeoxyribonucleotides inhibit proliferation of non-small cell lung cancer.
    Robinson LA; Smith LJ; Fontaine MP; Kay HD; Mountjoy CP; Pirruccello SJ
    Ann Thorac Surg; 1995 Dec; 60(6):1583-91. PubMed ID: 8787447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense anticancer oligonucleotide therapeutics.
    Wang H; Prasad G; Buolamwini JK; Zhang R
    Curr Cancer Drug Targets; 2001 Nov; 1(3):177-96. PubMed ID: 12188878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense approaches for the treatment of cancer.
    Monia BP; Holmlund J; Dorr FA
    Cancer Invest; 2000; 18(7):635-50. PubMed ID: 11036471
    [No Abstract]   [Full Text] [Related]  

  • 20. Antisense therapy in oncology: new hope for an old idea?
    Tamm I; Dörken B; Hartmann G
    Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.